



**ASX Announcement**

**25<sup>th</sup> July 2023**

## **Atomo Investor Webinar Presentation**

Atomo Diagnostics Limited (ASX:AT1) will release its Q4 FY23 Results on 27<sup>th</sup> July 2023.

A results briefing webinar for analysts and investors, hosted by Managing Director & CEO, John Kelly and CFO, Will Souter, will be held on Thursday, 27 July 2023 at 9.30am (AEST).

To access the webinar please pre-register via the following link:

[https://us02web.zoom.us/webinar/register/2816902470520/WN\\_R-mXghRWRtKlzvA5jsUg7w](https://us02web.zoom.us/webinar/register/2816902470520/WN_R-mXghRWRtKlzvA5jsUg7w)

~ ENDS ~

**For more information, please contact:**

**John Kelly**  
Managing Director & CEO  
e. [john.kelly@atomodiagnostics.com](mailto:john.kelly@atomodiagnostics.com)  
p. +61 401 922 279

**Investor Queries**  
[investorqueries@atomodiagnostics.com](mailto:investorqueries@atomodiagnostics.com)

*This announcement was authorised by the Managing Director & CEO.*

### **About Atomo**

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at [www.atomodiagnostics.com](http://www.atomodiagnostics.com)